An Evidence-based, Individualized Approach to the Management of Gastrointestinal Malignancies

View Activity

PROGRAM CHAIR

Johanna C. Bendell, MD
Chief Development Officer
Sarah Cannon Research Institute, LLC
Nashville, TN

FACULTY

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Medstar Georgetown University Hospital
Professor of Medicine and Oncology
Lombardi Comprehensive Cancer Center Georgetown University
Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer
Washington, DC

Jaffer A. Ajani, MD
Professor, Tenure Track
Department of Gastrointestinal (GI) Medical Oncology
Division of Cancer Medicine
Professor, Department of Epidemiology
Division of OVP, Cancer Prevention and Population Sciences
The University of Texas MD Anderson Cancer Center
Houston, TX

PROGRAM OVERVIEW

This case-based online activity will cover the treatment and management of patients with gastrointestinal cancers.

TARGET AUDIENCE

This activity is designed to meet the needs of medical oncologists, particularly community oncologists, oncology nurses, and other healthcare professionals involved in the care of patients with gastrointestinal cancers.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Review evidence and guideline recommendations for optimal sequencing of different treatment modalities across subsequent lines of therapy for advanced and metastatic gastric and (GC) and gastroesophageal junction (GEJ) cancers
  • Discuss strategies to individualize therapy for advanced and metastatic GC and GEJ cancers based on patient’s characteristics and biomarkers across lines of treatment
  • Review the clinical evidence of the prognostic and predictive value of anatomical characteristics and biomarkers profiling in guiding treatment selection for advanced and metastatic colorectal cancer (CRC) across lines of therapy
  • Review the biology of α-fetoprotein (AFP) in hepatocellular carcinoma (HCC) carcinogenesis; explain the clinical significance of elevated serum AFP; and discuss AFP’s role as a prognostic and predictive biomarker in HCC

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

Credit Designation Statement
Med Learning Group designates this online activity for a maximum of 2.0 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

Nursing Credit Information
Purpose:
This program would be beneficial for nurses involved in the treatment and management of patients with gastrointestinal cancers.

CNE Credits:
2.0 ANCC Contact Hour(s).

CNE Accreditation Statement
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 2.0 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Bendell has disclosed she has received the following funding: Gilead – research funding, consulting, travel; Genentech/Roche – research funding, consulting, travel; BMS – research funding, consulting, travel; Five Prime – research funding, consulting, DSMB; Lilly – research funding, consulting, travel; Merck – research funding, consulting, travel; MedImmune – research funding, consulting, travel’ Celgene – research funding, consulting, travel; EMD Serono – research funding; Taiho – research funding, consulting, travel; Macrogenics – research funding, consulting; GSK – research funding, consulting; Novartis – research funding, consulting, travel; OncoMed – research funding, consulting, travel; LEAP – research funding, consulting; TG Therapeutics – research funding, consulting; Astrazeneca – research funding, consulting; BI – research funding, consulting, travel; Daiichi Sankyo – research funding, consulting; Bayer – research funding, consulting; Incyte – research funding, consulting; Apexigen – research funding, consulting; Koltan – research funding; SynDevRx – research funding; Forty Seven – research funding; Abbvie – research funding; Array – research funding, consulting; Onyx – research funding; Sanofi – research funding, consulting; Takeda – research funding; Eisai – research funding ; Celldex – research funding; Agios – research funding; CytoMx – research funding; Nektar – research funding; ARMO – research funding, consulting, travel; Boston Biomedical – research funding; Ipsen – research funding, consulting, travel; Merrimack – research funding, consulting; Tarveda – research funding; Tyrogenex – research funding; Oncogenex – research funding, consulting, travel; Marshall Edwards – research funding; Pieris – research funding; Mersana – research funding; Calithera – research funding; Blueprint – research funding; Evelo – research funding; FORMA – research funding, consulting, travel; Merus – research funding; Jacobio – research funding; Blueprint – research funding; Effector – research funding; Novocure – research funding; Arrys – research funding; Tracon – research funding; Sierra – research funding; Innate – research funding; Arch Oncology – research funding, Consulting; Prelude Therapeutics – research funding, consulting; Phoenix Bio – consulting; Unum Therapeutics research funding; Vyriad – research funding; Harpoon – research funding; Cyteir – consulting; Molecular Partners – consulting; Innate – consulting; ADC – research funding; Torque – consulting; Tizona – consulting; Janssen – consulting; Tolero – consulting; TD2 (Translational Drug Development) – consulting; Amgen – research funding, consulting; Seattle Genetics – consulting; Moderna Therapeutics – consulting; Tanabe Research Laboratories – consulting; Beigene – research funding, consulting; Continuum Clinical – consulting; Cerulean – consulting; Pfizer – research funding; Millennium – research funding; Imclone – research funding; Acerta Pharma – research funding; and Rgenix – research funding.

Dr. Marshall has served as a speaker, consultant, and has contracted research for/with Genentech, Amgen, Bayer, Taiho Pharma, Celgene, Caris, and Merck.

Dr. Ajani has served as a consultant for Bristol-Meyers Squibb, Merck, Taiho, Eli Lilly, Astellas, and AstraZeneca. Dr. Ajani has also researched for Bristol-Meyers Squibb, Roche, Astellas, Taiho, Prolynx, Zymeworks, and Delta-Fly.

CME Content Review
The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Lisa Crenshaw, Senior Program Manager for Med Learning Group has nothing to disclose.
Chris Drury, MA, MA, Director of Medical and Scientific Services has nothing to disclose.
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the online evaluation.

Participants will receive their certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at https://www.medlearninggroup.com/privacy-policy/

RELEASE DATE: August 6, 2019

EXPIRATION DATE: August 6, 2020

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.